Stock AnalizXenon Pharmaceuticals Inc. XENE
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Xenon Pharmaceuticals Inc. (XENE) is a healthcare company listed in the US with a market value of about $4.0B. In fiscal year 2025 it had revenue of $8M and net income of -$346M, a net margin of -4612.1%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -27%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $0 | $0 | $9M | $18M | $32M | $7M | — | $311000 | $2M |
| Net income | -$346M | -$234M | -$182M | -$125M | -$79M | -$29M | -$42M | -$34M | -$31M | -$23M |
| Free cash flow | -$280M | -$184M | -$157M | -$104M | -$72M | -$51M | -$6M | -$35M | -$29M | -$20M |
| EPS (diluted) | $-4.36 | $-3.01 | $-2.73 | $-2.06 | $-1.77 | $-0.81 | $-1.54 | $-1.63 | $-1.72 | $-1.48 |
| Net margin | -4612.1% | — | — | -1329.0% | -427.9% | -89.6% | -609.1% | — | -9872.7% | -1275.5% |
| ROIC | -50.0% | -35.9% | -22.8% | -13.9% | -14.1% | -17.8% | -39.5% | -32.0% | -59.9% | -30.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $71.69, 77% above the current price; targets range from $46.00 to $90.00; the consensus rating is “Strong buy”; expected EPS is $-4.57 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Xenon Pharmaceuticals pay a dividend?
Not currently.
Is Xenon Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Xenon Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.